Advertisement

Current Hepatitis Reports

, Volume 9, Issue 4, pp 260–269 | Cite as

Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony

  • Shailaja Jamma
  • Ghazi Hussain
  • Daryl T.-Y. LauEmail author
Article

Abstract

Hepatitis B and hepatitis C are important causes of chronic liver disease globally. Although HBV/HCV coinfection is not uncommon, its epidemiology is poorly defined. Numerous studies provided evidence that coinfection accelerates liver disease progression and increases the risk of hepatocellular carcinoma. By applying new cell culture models to examine the interaction of both viruses, investigators concluded that HBV and HCV replicate in the same hepatocyte without interference. The roles of innate and adaptive immunity in determining the viral replication and disease outcomes still need rigorous investigation. To date, no standard-of-care recommendation exists for HBV/HCV coinfection. Pegylated interferon and ribavirin combination therapy demonstrated similar efficacy in suppressing HCV RNA in coinfection and HCV monoinfection. However, HBV reactivation during therapy can be a challenge. Future clinical trials evaluating the addition of a nucleoside/nucleotide analog for selective patients with HBV/HCV coinfection are essential for successful management of HBV/HCV coinfection.

Keywords

Hepatitis B virus Hepatitis C virus Epidemiology Natural history Pathogenesis Pegylated interferon 

Notes

Disclosure

The author has served on advisory boards for, and received research grants, honoraria, and travel reimbursements from, Bristol-Myers Squibb and Gilead.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance

  1. 1.
    Koff RS: Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J Clin Gastroenterol 2001, 33:20–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Brass V, Moradpour D: New insights into hepatitis B and C virus co-infection. J Hepatol 2009, 51:423–425.CrossRefPubMedGoogle Scholar
  3. 3.
    Liaw YF, Tsai SL, Chang JJ, et al.: Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994, 106:1048–1053.PubMedGoogle Scholar
  4. 4.
    Zarski JP, Bohn B, Bastie A, et al.: Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998, 28:27–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Pasquinelli C, Shoenberger JM, Chung J, et al.: Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 1997, 25:719–727.CrossRefPubMedGoogle Scholar
  6. 6.
    Chen SY, Kao CF, Chen CM, et al.: Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003, 278:591–607.CrossRefPubMedGoogle Scholar
  7. 7.
    Schuttler CG, Fiedler N, Schmidt K, et al.: Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002, 37:855–862.CrossRefPubMedGoogle Scholar
  8. 8.
    •• Eyre NS, Phillips RJ, Bowden S, et al.: Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol 2009, 51:446–457. This study demonstrated absence of direct interference between HBV and HCV in a highly reproducible cell culture system.CrossRefPubMedGoogle Scholar
  9. 9.
    •• Bellecave P, Gouttenoire J, Gajer M, et al.: Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009, 50:46–55. This study independently concluded that cells with replicating HBV could be infected by HCV without superinfection exclusion.CrossRefPubMedGoogle Scholar
  10. 10.
    Gaeta GB, Stornaiuolo G, Precone DF, et al.: Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003, 39:1036–1041.CrossRefPubMedGoogle Scholar
  11. 11.
    Liaw YF: Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995, 22(4 Pt 1):1101–1108.PubMedGoogle Scholar
  12. 12.
    Semnani S, Roshandel G, Abdolahi N, et al.: Hepatitis B/C virus co-infection in Iran: a seroepidemiological study. Turk J Gastroenterol 2007, 18:20–21.PubMedGoogle Scholar
  13. 13.
    Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556–562.CrossRefPubMedGoogle Scholar
  14. 14.
    El-Sherif A, Abou-Shady M, Abou-Zeid H, et al.: Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients. J Gastroenterol 2009, 44:359–364.CrossRefPubMedGoogle Scholar
  15. 15.
    Helmy A, Al-Sebayel MI: Isolated antibody to hepatitis B core antigen in patients with chronic hepatitis C virus infection. World J Gastroenterol 2006, 12:4406–4410.PubMedGoogle Scholar
  16. 16.
    Kazemi-Shirazi L, Petermann D, Muller C: Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C. J Hepatol 2000, 33:785–790.CrossRefPubMedGoogle Scholar
  17. 17.
    Rodriguez M, Navascues CA, Martinez A, et al.: Hepatitis C virus infection in patients with acute hepatitis B. Infection 1992, 20:316–319.CrossRefPubMedGoogle Scholar
  18. 18.
    Liaw YF, Chu CM, Chang-Chien CS, Wui CS: Simultaneous acute infections with hepatitis non-A, non-B, and B viruses. Dig Dis Sci 1982, 27:762–764.CrossRefPubMedGoogle Scholar
  19. 19.
    Feray C, Gigou M, Samuel D, et al.: Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993, 104:549–555.PubMedGoogle Scholar
  20. 20.
    Wu JC, Chen CL, Hou MC, et al.: Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitations of the polymerase chain reaction. Hepatology 1994, 19:836–840.CrossRefPubMedGoogle Scholar
  21. 21.
    Mimms LT, Mosley JW, Hollinger FB, et al.: Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 1993, 307:1095–1097.CrossRefPubMedGoogle Scholar
  22. 22.
    Coppola N, Marrocco C, Di Caprio D, et al.: Acute hepatitis B and C virus coinfection: a virological and clinical study of 3 cases. Clin Infect Dis 2003, 36:528–532.CrossRefPubMedGoogle Scholar
  23. 23.
    Chu CM, Sheen IS, Liaw YF: The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. Gastroenterology 1994, 107:189–195.PubMedGoogle Scholar
  24. 24.
    Pontisso P, Ruvoletto MG, Fattovich G, et al.: Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993, 105:1529–1533.PubMedGoogle Scholar
  25. 25.
    Liaw YF, Lin SM, Sheen IS, Chu CM: Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination. Infection 1991, 19:250–251.CrossRefPubMedGoogle Scholar
  26. 26.
    Tandon BN, Irshad M, Acharya SK, Joshi YK: Hepatitis C virus infection is the major cause of severe liver disease in India. Gastroenterol Jpn 1991, 26(Suppl 3):192–195.PubMedGoogle Scholar
  27. 27.
    Liaw YF, Yeh CT, Tsai SL: Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000, 95:2978–2980.CrossRefPubMedGoogle Scholar
  28. 28.
    • Sagnelli E, Coppola N, Pisaturo M, et al.: HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology 2009, 49:1090–1097. This article describes a long-term follow-up Italian study on the outcome of hepatitis C after HBV superinfection. A proportion of patients had prolonged HCV RNA clearance after HBV superinfection.CrossRefPubMedGoogle Scholar
  29. 29.
    Fukuda R, Ishimura N, Niigaki M, et al.: Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999, 58:201–207.CrossRefPubMedGoogle Scholar
  30. 30.
    Koike K, Kobayashi M, Gondo M, et al.: Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998, 54:249–255.CrossRefPubMedGoogle Scholar
  31. 31.
    Pollicino T, Squadrito G, Cerenzia G, et al.: Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004, 126:102–110.CrossRefPubMedGoogle Scholar
  32. 32.
    Cacciola I, Pollicino T, Squadrito G, et al.: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999, 341:22–26.CrossRefPubMedGoogle Scholar
  33. 33.
    Colombari R, Dhillon AP, Piazzola E, et al.: Chronic hepatitis in multiple virus infection: histopathological evaluation. Histopathology 1993, 22:319–325.CrossRefPubMedGoogle Scholar
  34. 34.
    Kao JH, Chen PJ, Lai MY, Chen DS: Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002, 40:4068–4071.CrossRefPubMedGoogle Scholar
  35. 35.
    Fong TL, Di Bisceglie AM, Waggoner JG, et al.: The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991, 14:64–67.CrossRefPubMedGoogle Scholar
  36. 36.
    Mohamed Ael S, al Karawi MA, Mesa GA: Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997, 44:1404–1406.PubMedGoogle Scholar
  37. 37.
    Tanaka H, Tsukuma H, Yamano H, et al.: Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 2004, 112:1075–1080.CrossRefPubMedGoogle Scholar
  38. 38.
    Kew MC, Yu MC, Kedda MA, et al.: The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997, 112:184–187.CrossRefPubMedGoogle Scholar
  39. 39.
    Benvegnu L, Fattovich G, Noventa F, et al.: Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994, 74:2442–2448.CrossRefPubMedGoogle Scholar
  40. 40.
    Donato F, Boffetta P, Puoti M: A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998, 75:347–354.CrossRefPubMedGoogle Scholar
  41. 41.
    Chiaramonte M, Stroffolini T, Vian A, et al.: Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999, 85:2132–2137.CrossRefPubMedGoogle Scholar
  42. 42.
    Guptan RC, Thakur V, Raina V, Sarin SK: Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol 1999, 14:893–898.CrossRefPubMedGoogle Scholar
  43. 43.
    Hasegawa I, Orito E, Tanaka Y, et al.: Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int 2005, 25:247–253.CrossRefPubMedGoogle Scholar
  44. 44.
    Liaw YF, Chien RN, Lin SM, et al.: Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997, 17:449–452.CrossRefPubMedGoogle Scholar
  45. 45.
    Villa E, Grottola A, Buttafoco P, et al.: High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001, 96:2973–2977.PubMedGoogle Scholar
  46. 46.
    Weltman MD, Brotodihardjo A, Crewe EB, et al.: Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995, 2:39–45.CrossRefPubMedGoogle Scholar
  47. 47.
    Zignego AL, Fontana R, Puliti S, et al.: Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997, 51:313–318.CrossRefPubMedGoogle Scholar
  48. 48.
    Chuang WL, Dai CY, Chang WY, et al.: Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005, 10:125–133.PubMedGoogle Scholar
  49. 49.
    Fabris P, Brown D, Tositti G, et al.: Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004, 29:160–166.CrossRefPubMedGoogle Scholar
  50. 50.
    Hung CH, Lee CM, Lu SN, et al.: Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005, 20:727–732.CrossRefPubMedGoogle Scholar
  51. 51.
    Liu CJ, Chen PJ, Lai MY, et al.: Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003, 37:568–576.CrossRefPubMedGoogle Scholar
  52. 52.
    Mrani S, Chemin I, Menouar K, et al.: Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol 2007, 79:1075–1081.CrossRefPubMedGoogle Scholar
  53. 53.
    Myers RP, Thibault V, Poynard T: The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. J Viral Hepat 2003, 10:103–110.CrossRefPubMedGoogle Scholar
  54. 54.
    •• Liu CJ, Chuang WL, Lee CM, et al.: Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009, 136:496–504 e3. This article describes the largest prospective, randomized, controlled trial using pegylated interferon and ribavirin therapy on HBV and HCV coinfection. This Taiwanese study confirmed high HCV SVR but also high rate of HBV reactivation during combination therapy.CrossRefPubMedGoogle Scholar
  55. 55.
    • Potthoff A, Wedemeyer H, Boecher WO, et al.: The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008, 49:688–694. This study reported that HCV genotype 1 and non-1 patients both had excellent SVR in the setting of co-infection. They observed four patients with undetectable serum HBV DNA at baseline had reactivation of HBV after HCV RNA clearance.CrossRefPubMedGoogle Scholar
  56. 56.
    Senturk H, Tahan V, Canbakan B, et al.: Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers. Neth J Med 2008, 66:191–195.PubMedGoogle Scholar
  57. 57.
    • Yu JW, Sun LJ, Zhao YH, et al.: Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int 2009, 29:1485–1493. This study showed that HBV reactivation rate was significantly higher among those who achieved HCV SVR compared to those without SVR.CrossRefPubMedGoogle Scholar
  58. 58.
    Marrone A, Zampino R, D’Onofrio M, et al.: Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol 2004, 41:1064–1065.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Shailaja Jamma
    • 1
  • Ghazi Hussain
    • 1
  • Daryl T.-Y. Lau
    • 1
    Email author
  1. 1.Liver Center, Division of Gastroenterology, Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonUSA

Personalised recommendations